African Pharmaceutical Review.

African Pharmaceutical Review.

GSK’s fully liquid meningococcal vaccine approved in Europe

GSK’s fully liquid meningococcal vaccine approved in Europe


Global biopharmaceutical company GSK has announced that its single-vial, fully liquid form of the Meningococcal Group A, C, W-135, and Y conjugate vaccine (Menveo) has been approved by the European Commission to help prevent invasive meningococcal disease caused by four bacterial serogroups; A, C, W, and Y.

GSK’s regulatory submission and subsequent approval were backed by data from two phase IIb trials that demonstrated that the fully liquid form of Menveo has comparable immunogenicity, safety profile, and tolerability to the lyophilized version.

The company has clarified that the original lyophilized formulation that requires reconstitution and which was approved by the EMA in 2010 remains “unaffected” by this new approval.


READ ALSO: Novartis’ innovative breast cancer medicine gets approval in Europe


Therefore, the fully liquid version introduces an option that is more efficient in delivering protection against a disease that has caused suffering to many through neurological damage, amputations, hearing loss, nervous system problems, as well as death.

It is now licensed for the active immunization of adults, adolescents, and children starting at age 2, providing medical professionals with a choice that doesn't require reconstitution prior to use.

"As a leader in meningococcal vaccines, GSK is dedicated to finding innovative solutions that simplify immunization and support vaccine uptake. We remain committed to safeguarding individuals from bacterial meningitis, and we will persist in our efforts to prevent this devastating disease among at-risk populations in the European Union," stated Philip Dormitzer, GSK Head of Global Vaccines Research & Development.


Did you find this informative? Subscribe for more.


 

img
Writer

APR Team

African Pharmaceutical Review team dedicated to providing the latest news, insights and developments from the pharma, biotech and medtech industries.